Press release content from Globe Newswire. The AP news staff was not involved in its creation. T-knife Therapeutics Announces the Appointment of Donald Wuchterl as Senior Vice President and ... AKAMPIONApril 7, 2021 GMT San Francisco, CA / Berlin, Germany – April 7, 2021 — T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing innovative therapeutics for the benefit of solid tumor patients and their families, today announced the appointment of Donald Wuchterl as Senior Vice President and Chief Manufacturing Officer. In this newly appointed role, Mr. Wuchterl will oversee process and analytical development, quality assurance and quality control, and viral vector and cell therapy manufacturing activities. “I am very pleased to welcome Don to the T-knife team,” stated Thomas M. Soloway, Chief Executive Officer of T-knife. “Don’s proven track-record of building and leading highly functioning cell therapy, biologics and gene therapy manufacturing organizations will be a significant asset to our platform and development programs. We look forward to the contributions Don will make as we advance our lead program targeting MAGE-A1 into the clinic later this year and continue to build a leading pipeline of innovative TCR-T product candidates.”